These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38498130)

  • 1. Modeling of Mouse Experiments Suggests that Optimal Anti-Hormonal Treatment for Breast Cancer is Diet-Dependent.
    Akman T; Arendt LM; Geisler J; Kristensen VN; Frigessi A; Köhn-Luque A
    Bull Math Biol; 2024 Mar; 86(4):42. PubMed ID: 38498130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
    Schech A; Yu S; Goloubeva O; McLenithan J; Sabnis G
    Endocr Relat Cancer; 2015 Aug; 22(4):645-56. PubMed ID: 26113604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.
    Barone I; Cui Y; Herynk MH; Corona-Rodriguez A; Giordano C; Selever J; Beyer A; Andò S; Fuqua SA
    Cancer Res; 2009 Jun; 69(11):4724-32. PubMed ID: 19487288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
    Liu H; Wang J; Zhang M; Xuan Q; Wang Z; Lian X; Zhang Q
    Breast Cancer Res Treat; 2017 Nov; 166(1):95-107. PubMed ID: 28730338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
    Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microenvironmental growth factors induce long-term estrogen deprivation resistance in breast cancer.
    Tsuboi K; Uematsu C; Yamaguchi Y; Niwa T; Hayashi SI
    Breast Cancer; 2019 Nov; 26(6):748-757. PubMed ID: 31119683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
    Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for Enhanced Exosome Production in Aromatase Inhibitor-Resistant Breast Cancer Cells.
    Augimeri G; La Camera G; Gelsomino L; Giordano C; Panza S; Sisci D; Morelli C; Győrffy B; Bonofiglio D; Andò S; Barone I; Catalano S
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
    Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
    Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
    Chen Z; Wang Y; Warden C; Chen S
    J Steroid Biochem Mol Biol; 2015 May; 149():118-27. PubMed ID: 25683269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Hanamura T; Hayashi SI
    Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
    Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
    PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
    Bacci M; Giannoni E; Fearns A; Ribas R; Gao Q; Taddei ML; Pintus G; Dowsett M; Isacke CM; Martin LA; Chiarugi P; Morandi A
    Cancer Res; 2016 Mar; 76(6):1615-26. PubMed ID: 26795347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.
    Varešlija D; McBryan J; Fagan A; Redmond AM; Hao Y; Sims AH; Turnbull A; Dixon JM; Ó Gaora P; Hudson L; Purcell S; Hill AD; Young LS
    Clin Cancer Res; 2016 Jun; 22(11):2765-77. PubMed ID: 26763249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
    Gao Q; López-Knowles E; Cheang MCU; Morden J; Ribas R; Sidhu K; Evans D; Martins V; Dodson A; Skene A; Holcombe C; Mallon E; Evans A; Bliss JM; Robertson J; Smith I; Martin LA; Dowsett M;
    Breast Cancer Res; 2019 Dec; 22(1):2. PubMed ID: 31892336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.
    Higuchi T; Endo M; Hanamura T; Gohno T; Niwa T; Yamaguchi Y; Horiguchi J; Hayashi S
    PLoS One; 2016; 11(5):e0155844. PubMed ID: 27228187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.